Abstract: Aspects of the present disclosure relate to retrospective memory analysis. In examples, a historical archive of memory images for an execution environment is maintained. A historical memory image of the historical archive may be evaluated according to a current set of known issues, rather than issues that were known at the time of the memory capture. Accordingly, it may be possible to determine when the execution environment was last in a good environment condition. As another example, it may be possible to determine whether a now-known issue has since been resolved (e.g., such that the issue would not be identified in the current execution environment). Thus, as compared to contemporaneous issue identification techniques, aspects of the present disclosure may be applied to any number of execution environments to enable retrospective identification of now-known issues that were, at least at the time of a memory capture, not known.

Abstract: Provided herein are low impurity compositions comprising a compound represented by Formula (I): which are useful in the treatment of disorders related to the activity of the c-KIT and PDGFR? kinases, and oncogenic forms thereof.

Abstract: A cable distribution system includes a head end connected to a plurality of customer devices through a transmission network that includes a first remote physical device, where the first remote physical device includes remote physical layer processing, that converts digital data to analog data suitable for the plurality of customer devices, where the head end includes at least one server each of which includes a respective processor.

Abstract: Provided herein are low impurity compositions comprising a compound represented by Formula (I): which are useful in the treatment of disorders related to the activity of the c-KIT and PDGFR? kinases, and oncogenic forms thereof

Abstract: The present invention relates to bispecific anti-CCL2 antibodies binding to two different epitopes on human CCL2, pharmaceutical compositions thereof, their manufacture, and use as medicaments for the treatment of cancers, inflammatory, autoimmune and ophthalmologic diseases.

Abstract: The present invention relates to compounds of formula I that function as inhibitors of RET (rearranged during transfection) kinase enzyme activity: wherein HET, X1, X2, X3, X4, integer a and R3 are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which RET kinase activity is implicated.

Abstract: Organs-on-chips are microfluidic devices for culturing living cells in micrometer sized chambers in order to model physiological functions of tissues and organs. Engineered patterning and continuous fluid flow in these devices has allowed culturing of intestinal cells bearing physiologically relevant features and sustained exposure to bacteria while maintaining cellular viability, thereby allowing study of inflammatory bowl diseases. However, existing intestinal cells do not possess all physiologically relevant subtypes, do not possess the repertoire of genetic variations, or allow for study of other important cellular actors such as immune cells. Use of iPSC-derived epithelium, including IBD patient-specific cells, allows for superior disease modeling by capturing the multi-faceted nature of the disease.

Abstract: A wearable device for an attraction system includes a display, a projector oriented at a first oblique angle with respect to the display and configured to project an image onto the display, and a microphone oriented at a second oblique angle with respect to the display. The microphone is configured to receive audio waves deflecting off the display.

Abstract: A resin including up to 99.99 weight percent (wt. %) of a first polyolefin grafted with a functional group selected from an ethylenically unsaturated carboxylic acid, a carboxylic acid anhydride, an ester functional group or a combination thereof; and 0.01 to 3.0 wt. % of a tin oxide-based catalyst, where the resin includes 0.2 wt. % to 1.5 wt. % of the functional group from the first polyolefin, the wt. % based on a total weight of the resin. The first polyolefin can be selected from a polyethylene, a polypropylene, an ethylene/alpha-olefin copolymer, a propylene/alpha-olefin copolymer and combinations thereof. The tin oxide-based catalyst can be selected from dibutyltin oxide, dioctyltin oxide and combinations thereof. The resin can be used in a multilayer structure, where a Layer A comprises the resin and a Layer B comprises a polyester, where a first major surface of Layer A is in adhering contact with the second major surface of Layer B.

Abstract: The present invention relates to novel protein pores and their uses in analyte detection and characterisation. The invention particularly relates to an isolated pore complex formed by a CsgG-like pore and a modified CsgF peptide, or a homologue or mutant thereof, thereby incorporating an additional channel constriction or reader head in the nanopore. The invention further relates to a transmembrane pore complex and methods for production of the pore complex and for use in molecular sensing and nucleic acid sequencing applications.

Abstract: A radar-based environmental detection system for motor vehicles. The system includes at least one radar sensor for providing location data regarding objects in the environment of the motor vehicle, and including a neural network for converting the location data into an environmental model which represents spatio-temporal object data of the objects. The neural network is conditioned to give priority to outputting environmental models in which at least one predetermined physical relationship between the location data and the object data is satisfied.

Abstract: The invention relates to a process for carrying out reactions on preheated particles, comprising: (a) providing particles in a buffer container; (b) feeding the particles from the buffer container into a reactor via a feed line; (c) withdrawing the particles from the reactor, wherein the particles are heated in the feed line.

Abstract: Methods, apparatus, systems and articles of manufacture are disclosed for electric motorized wheel assemblies. An example wheel assembly for use with an electric vehicle disclosed herein includes an electric motor, a suspension assembly, and a frame mounting interface to attach the wheel assembly to a frame of the electric vehicle.

Abstract: Provided herein are low impurity compositions comprising a compound represented by Formula (I): which are useful in the treatment of disorders related to the activity of the c-KIT and PDGFR? kinases, and oncogenic forms thereof.

Abstract: A leading edge structure (1) for a flow control system of an aircraft (101) including a double-walled leading edge panel (3) with a first side portion (11) extending to a first attachment end (17), a second side portion (13) extending to a second attachment end (19), an inner wall element (21) facing a plenum (7), an outer wall element (23) facing ambient flow (25), and a core assembly (97). The outer wall element (23) includes micro pores (31) and the inner wall element (21) includes openings (33) which form a fluid connection from ambient flow, through the core assembly (97) and to the plenum (7). The thickness of the outer wall element is reduced due to the first attachment end (17) and/or at the second attachment end (19) attached to the inner wall element (21) by both bonding and fasteners (85, 87, 89, 91).

Abstract: The present invention relates to bispecific anti-CCL2 antibodies binding to two different epitopes on human CCL2, pharmaceutical compositions thereof, their manufacture, and use as medicaments for the treatment of cancers, inflammatory, autoimmune and ophthalmologic diseases.

Abstract: Provided herein are low impurity compositions comprising a compound represented by Formula (I): which are useful in the treatment of disorders related to the activity of the c-KIT and PDGFR? kinases, and oncogenic forms thereof.

Abstract: Dynamically generating data tests includes: receiving test templates and metadata for a plurality of data objects and, on a trigger condition: based on at least the metadata and the test templates, determining a current set of templated data tests, wherein determining the current set of templated data tests comprises: determining at least one templated data test, from a prior set of templated data tests, to cease using; determining at least one templated data test to add to the current set of templated data tests; and determining, within the current set of templated data tests, at least one templated data tests to regenerate; generating the at least one templated data test to add to the current set of templated data tests; regenerating the least one templated data test to regenerate; and executing templated data tests, within the set of current templated data tests, on the plurality of data objects.

Abstract: The application relates to a method for determining at least one speed component of a fluid stream, in particular for laser Doppler anemometry, the method having at least the steps of: —providing at least a first part-beam and a second part-beam; —directing the first part-beam along a first optical path and directing the second part-beam along a second optical path onto a superimposition region within the fluid stream so that the first optical path and the second optical path intersect in the superimposition region; —detecting a Doppler-shifted first part-beam scattered light signal, which was back-scattered by tracer particles in the fluid stream in the superimposition region, at least partially following the first optical path; —detecting a Doppler-shifted solid angle scattered light signal, which was scattered by the tracer particles in the superimposition region into a path different at least from the first optical path and from the second optical path.

Abstract: Provided herein are low impurity compositions comprising a compound represented by Formula (I): which are useful in the treatment of disorders related to the activity of the c-KIT and PDGFR? kinases, and oncogenic forms thereof.